Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Cell Stem Cell|November 3, 2010
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletionJae Y Lee, Daisuke Nakada, Omer H Yilmaz, et al.
Cell|February 27, 2007
The retinoblastoma binding protein RBP2 is an H3K4 demethylaseRobert J Klose, Qin Yan, Zuzana Tothova, et al.
British Journal of Haematology|October 18, 2005
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesAyalew Tefferi, Terra L Lasho, Susan M Schwager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2004
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsM Golam Mohi, Christina Boulton, Ting-Lei Gu, et al.
British Journal of Haematology|October 4, 2005
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevanceAlexandra P Wolanskyj, Terra L Lasho, Susan M Schwager, et al.
Cell Stem Cell|September 13, 2008
Notch signaling specifies megakaryocyte development from hematopoietic stem cellsThomas Mercher, Melanie G Cornejo, Christopher Sears, et al.
Blood|October 31, 2002
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3Karsten Spiekermann, Ralf J Dirschinger, Ruth Schwab, et al.
Blood|April 30, 2005
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromesDavid P Steensma, Gordon W Dewald, Terra L Lasho, et al.
Leukemia|October 22, 2004
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)R L Levine, M Wadleigh, D W Sternberg, et al.
Blood|July 30, 2008
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitorsThomas Kindler, Melanie G Cornejo, Claudia Scholl, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Cell Stem Cell|November 3, 2010
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletionJae Y Lee, Daisuke Nakada, Omer H Yilmaz, et al.
Cell|February 27, 2007
The retinoblastoma binding protein RBP2 is an H3K4 demethylaseRobert J Klose, Qin Yan, Zuzana Tothova, et al.
British Journal of Haematology|October 18, 2005
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesAyalew Tefferi, Terra L Lasho, Susan M Schwager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2004
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsM Golam Mohi, Christina Boulton, Ting-Lei Gu, et al.
British Journal of Haematology|October 4, 2005
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevanceAlexandra P Wolanskyj, Terra L Lasho, Susan M Schwager, et al.
Cell Stem Cell|September 13, 2008
Notch signaling specifies megakaryocyte development from hematopoietic stem cellsThomas Mercher, Melanie G Cornejo, Christopher Sears, et al.
Blood|October 31, 2002
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3Karsten Spiekermann, Ralf J Dirschinger, Ruth Schwab, et al.
Blood|April 30, 2005
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromesDavid P Steensma, Gordon W Dewald, Terra L Lasho, et al.
Leukemia|October 22, 2004
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)R L Levine, M Wadleigh, D W Sternberg, et al.
Blood|July 30, 2008
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitorsThomas Kindler, Melanie G Cornejo, Claudia Scholl, et al.
Pageof 19